Reduction of soluble CD163, substance P, programmed death 1 and inflammatory markers: phase 1B trial of aprepitant in HIV-1-infected adults

OBJECTIVE: We evaluated safety, antiviral, immunomodulatory and anti-inflammatory properties of aprepitant – a neurokinin 1 receptor antagonist. DESIGN: Phase IB randomized, placebo-controlled, double-blinded study. METHODS: Eighteen patients were randomized (nine to aprepitant and nine to placebo)....

Descripción completa

Detalles Bibliográficos
Autores principales: Tebas, Pablo, Spitsin, Sergei, Barrett, Jeffrey S., Tuluc, Florin, Elci, Okan, Korelitz, James J., Wagner, Wayne, Winters, Angela, Kim, Deborah, Catalano, Renae, Evans, Dwight L., Douglas, Steven D.
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Lippincott Williams & Wilkins 2015
Materias:
Clinical Science
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4472318/
https://www.ncbi.nlm.nih.gov/pubmed/25915168
http://dx.doi.org/10.1097/QAD.0000000000000638

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4472318/
https://www.ncbi.nlm.nih.gov/pubmed/25915168
http://dx.doi.org/10.1097/QAD.0000000000000638

Ejemplares similares